Tags

Type your tag names separated by a space and hit enter

Feverfew for preventing migraine.
Cochrane Database Syst Rev 2000; (3):CD002286CD

Abstract

BACKGROUND

Feverfew (Tanacetum parthenium L.) is a popular herbal remedy for migraine.

OBJECTIVES

To systematically review the evidence for or against the efficacy of feverfew versus placebo for the prevention of migraine.

SEARCH STRATEGY

Electronic literature searches were performed using the databases CISCOM (Research Council for Complementary Medicine, London, UK), MEDLINE, EMBASE, Biosis and the Cochrane Library (each from its inception to April 1998). Manufacturers were contacted and the bibliographies of identified articles checked for further trials.

SELECTION CRITERIA

Randomised, placebo-controlled, double-blind trials assessing the efficacy of feverfew for preventing migraine were included. No restrictions regarding the language of publication were imposed.

DATA COLLECTION AND ANALYSIS

Data on patients, interventions, methods, outcomes and results were extracted in a pre-defined, standardised manner. Methodological quality was evaluated using the scoring system developed by Jadad and colleagues. Both data extraction and the assessment of methodological quality were performed independently by two reviewers.

MAIN RESULTS

Four trials met the inclusion criteria. The majority of these trials suggested beneficial effects of feverfew compared with placebo. However, the trial with the highest methodological quality, which was also among the largest, found no significant difference between feverfew and placebo.

REVIEWER'S CONCLUSIONS

The efficacy of feverfew for the prevention of migraine has not been established beyond reasonable doubt.

Authors+Show Affiliations

Department of Complementary Medicine, School of Postgraduate Medicine & Health Sciences, University of Exeter, United Kingdom, 25 Victoria Park Road, Exeter, Devon, UK, EX2 4NT. M.H.Pittler@exeter.ac.ukNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Review
Systematic Review

Language

eng

PubMed ID

10908545

Citation

Pittler, M H., et al. "Feverfew for Preventing Migraine." The Cochrane Database of Systematic Reviews, 2000, p. CD002286.
Pittler MH, Vogler BK, Ernst E. Feverfew for preventing migraine. Cochrane Database Syst Rev. 2000.
Pittler, M. H., Vogler, B. K., & Ernst, E. (2000). Feverfew for preventing migraine. The Cochrane Database of Systematic Reviews, (3), p. CD002286.
Pittler MH, Vogler BK, Ernst E. Feverfew for Preventing Migraine. Cochrane Database Syst Rev. 2000;(3)CD002286. PubMed PMID: 10908545.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Feverfew for preventing migraine. AU - Pittler,M H, AU - Vogler,B K, AU - Ernst,E, PY - 2000/7/25/pubmed PY - 2001/7/6/medline PY - 2000/7/25/entrez SP - CD002286 EP - CD002286 JF - The Cochrane database of systematic reviews JO - Cochrane Database Syst Rev IS - 3 N2 - BACKGROUND: Feverfew (Tanacetum parthenium L.) is a popular herbal remedy for migraine. OBJECTIVES: To systematically review the evidence for or against the efficacy of feverfew versus placebo for the prevention of migraine. SEARCH STRATEGY: Electronic literature searches were performed using the databases CISCOM (Research Council for Complementary Medicine, London, UK), MEDLINE, EMBASE, Biosis and the Cochrane Library (each from its inception to April 1998). Manufacturers were contacted and the bibliographies of identified articles checked for further trials. SELECTION CRITERIA: Randomised, placebo-controlled, double-blind trials assessing the efficacy of feverfew for preventing migraine were included. No restrictions regarding the language of publication were imposed. DATA COLLECTION AND ANALYSIS: Data on patients, interventions, methods, outcomes and results were extracted in a pre-defined, standardised manner. Methodological quality was evaluated using the scoring system developed by Jadad and colleagues. Both data extraction and the assessment of methodological quality were performed independently by two reviewers. MAIN RESULTS: Four trials met the inclusion criteria. The majority of these trials suggested beneficial effects of feverfew compared with placebo. However, the trial with the highest methodological quality, which was also among the largest, found no significant difference between feverfew and placebo. REVIEWER'S CONCLUSIONS: The efficacy of feverfew for the prevention of migraine has not been established beyond reasonable doubt. SN - 1469-493X UR - https://www.unboundmedicine.com/medline/citation/10908545/Feverfew_for_preventing_migraine_ L2 - https://doi.org/10.1002/14651858.CD002286 DB - PRIME DP - Unbound Medicine ER -